Immunome
IMNM
26 hedge funds and large institutions have $7.35M invested in Immunome in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 7 closing their positions.
2.43% less ownership
Funds ownership: 22.27% → 19.84% (-2.4%)
10% less funds holding
Funds holding: 29 → 26 (-3)
28% less capital invested
Capital invested by funds: $10.2M → $7.35M (-$2.87M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$47.9K |
| 2 |
TC
Titleist Capital
San Antonio,
Texas
|
+$36.4K |
| 3 |
Renaissance Technologies
New York
|
+$27.3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.58K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$7.14K |
Top Sellers
IMNM Hedge Fund Activity: Q2 2022 in Review
26 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q2 2022, worth a combined $7.35M — down 28% from $10.2M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of IMNM and 4 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 4 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $47.9K. The largest seller was Alpine Global Management, cutting an estimated $579K.
- 26 institutional investors held Immunome (IMNM) as of Q2 2022, down from 29 in Q1 2022.
- Funds reported $7.35M of Immunome stock for Q2 2022, down 28% quarter-over-quarter.
- 4 funds opened new Immunome positions in Q2 2022 and 7 closed out, a net change of -3 holders.
- The largest Immunome buyer in Q2 2022 was Citadel Advisors, an estimated $47.9K added.
- The largest Immunome seller in Q2 2022 was Alpine Global Management, an estimated $579K sold.
Based on aggregated 13F filings for Q2 2022.